Abstract: The present invention relates to a series of new drugs which refer to chemical series capable of catalyzing the decomposition of H2O2 to generate singlet oxygen (1O2). The drugs relate to therapeutic mechanisms, different from traditional photodynamic therapy, in which the specific affinity of photofrin to focus, such as tumors, vascular plaques and skin diseases is utilized. The activation of photofrin is carried out by specific protein binding or by electron beam, x-ray, r-ray, or other means, to focus, catalyze the decomposition reaction of H2O2 to generate 1O2 in the focus, 1O2 further induces apoptosis and necrosis of cells with pathological changes. The drugs are useful in tumors, vascular plaques and skin diseases, and cosmetic effects on skin are prompted. The drugs obtained via the screening and studying of the present invention are used for chemodynamic therapy (CDT), or for radiochemodynamic therapy (RCDT) carried out via radioactive rays.

Abstract: The invention relates to the field of medicament use, in particular to the clinical use of carbamide peroxide injection series for virus inactivation in the treatment of blood vessel plaque, leukemia, AIDS and hepatitis, etc. The invention utilizes the affinity of photosensitizers to blood vessel plaque focus, leukemia cells, tumor, and/or virus, which is several times higher than that to normal tissues, so as to destroy focus cells or virus by generating sufficient singlet oxygen (1O2) under the effect of a method using laser, X-ray, ultrasound and medicament, etc., while in condition of using carbamide peroxide injection series. The effects for treating the above diseases are achieved efficiently without serious side effects to the normal human tissues and organs.

Abstract: The invention relates to the field of medicament use, in particular to the clinical use of photosensitizers for inactivating viruses in the treatment of blood vessel plaque, leukemia, AIDS, hepatitis and the like. The invention is based on the affinity of photosensitizer to blood vessel plaque focus, leukemia cells, tumor, and/or virus, which is several times higher than that to normal tissues, to destroy focus cells or virus by generating singlet oxygen (1O2) under the effect of a method using laser, X-ray, ultrasound and medicament. The effects for treating the above diseases are achieved without serious side effects to the normal human tissues and organs.

Abstract: The present disclosure relates to a compound comprising at least one of a carbon or an oxygen isotope and a process for preparing the compound. The process comprises irradiating a compound comprising at least one of a carbon or an oxygen atom using photons or particles having an energy in the range of 20 MeV-430 MeV. The carbon and/or the oxygen atom is then allowed to be converted into a carbon and/or an oxygen positron nuclide through a photonuclear reaction. Provided that the molecular structure of the compound is not disrupted, the compound comprising the carbon and/or the oxygen isotope is prepared. The compound may be used in positron and/or other nuclide imaging to obtain a distribution and/or metabolic image of the compound in a human and/or animal body.

Abstract: The present invention relates to a series of new drugs which refer to chemical series capable of catalyzing the decomposition of H2O2 to generate singlet oxygen (1O2). The drugs relate to therapeutic mechanisms, different from traditional photodynamic therapy, in which the specific affinity of photofrin to focus, such as tumors, vascular plaques and skin diseases is utilized. The activation of photofrin is carried out by specific protein binding or by electron beam, x-ray, r-ray, or other means, to focus, catalyze the decomposition reaction of H2O2 to generate 1O2 in the focus, 1O2 further induces apoptosis and necrosis of cells with pathological changes. The drugs are useful in tumors, vascular plaques and skin diseases, and cosmetic effects on skin are prompted. The drugs obtained via the screening and studying of the present invention are used for chemodynamic therapy (CDT), or for radiochemodynamic therapy (RCDT) carried out via radioactive rays.

Abstract: The present disclosure relates to a compound comprising an oxygen-15 and a process for preparation thereof. It also relates to the use of the compound in positron and/or other nuclide imaging and use of the compound in obtaining a perfusion and/or metabolic image in an animal and/or human body. A process for preparing the compound comprises irradiating a compound comprising oxygen via irradiation energy in the range of 10 MeV to 430 MeV. The oxygen atom in the compound may then be allowed to be converted to an oxygen-15 positron nuclide through a photonuclear reaction. Provided that the molecular structure of the irradiated compound is not disrupted, a compound comprising an oxygen-15 is prepared.

Abstract: The present disclosure relates to a compound comprising at least one of a carbon or an oxygen isotope and a process for preparing the compound. The process comprises irradiating a compound comprising at least one of a carbon or an oxygen atom using photons or particles having an energy in the range of 20 MeV-430 MeV. The carbon and/or the oxygen atom is then allowed to be converted into a carbon and/or an oxygen positron nuclide through a photonuclear reaction. Provided that the molecular structure of the compound is not disrupted, the compound comprising the carbon and/or the oxygen isotope is prepared. The compound may be used in positron and/or other nuclide imaging to obtain a distribution and/or metabolic image of the compound in a human and/or animal body.